Dr Philippe Guillot-Chêne
Dr. Philippe Guillot-Chêne has 40 years of experience in the field of Pharmaceuticals and Biotechnology in areas going from Marketing and Sales management to Business acquisition. He received his PhD from the University of Lyon in 1980.
He then joined the Institut Merieux (now Sanofi Pasteur) International Division – Lyon where he had various positions of management, as VP Europe and VP Asie.
In 1992, he joined Parteurop as a partner and since then has been closely involved in deal negotiations and various aspects of acquisition, spin-offs and joint ventures.
From 2007 until 2010, he has been president of Humalys (Lyon, France), a French biotechnology company dedicated to the identification and development of therapeutic genuinely human monoclonal antibodies. Humalys has been acquired in 2010 by Vivalis (today Valvena). Dr. Guillot-Chêne has been a Board member of several biotechnology and pharmaceutical companies in France, Austria, UK and USA.
He was also Board member of the health division of the Rhône-Alpes Regional Agency for Development and Innovation (ARDI). He served as a consultant for the pharmaceutical and in vitro diagnostic industries, the French Blood Agency and the World Health Organization (WHO). He has been a founding partner of: Pelias AG, an Austrian biotechnology company, acquired by Intercell AG (Vienna, Austria), Humalys SA, a company dedicated to monoclonal antibodies, Abag SA (Now Ingen Biosciences) (Paris, France), a French biotechnology company focused on the search of new bacteria antigens for the in vitro diagnostic field and Eurabiolife (Lyon, France and Beijing, China), a company dedicated to business development activities in China.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE